Clinical Research Directory
Browse clinical research sites, groups, and studies.
Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia
Summary
This will be a systematic, combined, prospective assessment of the novel echographic, CMR, and PET imaging tools in newly-diagnosed patients with cardiac AL amyloidosis at baseline and after treatment.
Official title: Molecular, Magnetic Resonance, and Echocardiographic Imaging Combined With Biomarkers of Cardiac and Clonal Disease to Predict Survival and Assess Response to Therapy in Cardiac AL Amyloidosis
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
69
Start Date
2020-07-22
Completion Date
2025-06-30
Last Updated
2025-05-07
Healthy Volunteers
No
Conditions
Interventions
[18F]Florbetaben
Patients will undergo on the same day: * 18F-florbetaben PET-CT scans. The dose to be injected intravenously (6 second/mL) will be 370 MBq (for a 70 Kg patient); * standard assessment of clonal and organ disease; * echocardiography; * cardiac magnetic resonance. All the patients will undergo those evaluations at baseline and 6 months after treatment initiation.
Locations (1)
Fondazione IRCCS Policlinico San Matteo
Pavia, Italy